Biotech veteran Jodie Morrison on building drug ‘platforms’ and a support group for CEOs

The COVID-19 pandemic brought about job changes for many people — including biotech veteran Jodie Morrison.

Morrison has been in the business of building young biotechnology companies for many years, with executive stints over the past decade at startups like Tokai Pharmaceuticals and Syntimmune as well as more mature drugmakers such as Keryx Biopharmaceuticals. More recently, she was the CEO of Cadent Therapeutics, a small biotech focused on developing brain drugs. But even that role was one sale to Novartis, two new jobs and three years ago.